



Addressing Hidden Bottlenecks in Clinical Trials


Elben Guimaraes, Head of GMP Manufacturing, Aurora Biosynthetics

IMAPAC Clinical Trial Festival | Singapore | March 2026

Big Pharma Continues to Integrate RNA Modality

\$10.25B+ in acquisitions since January 2025

Six Acquisitions Over \$1B (2025-2026)




Australia Plays Key Role in Transformation

Uniquely combines deep R&D Tax Incentive, Five-Eyes alignment, and BIOSECURE-safe jurisdiction


Competitive Comparison

FACTOR	AUSTRALIA	OTHERS
R&D Tax Incentive 43.5% refundable, cash rebate	✓	✗
BIOSECURE-Friendly Allied jurisdiction	✓	!
Five-Eyes Geopolitical risk reduction Strong IP protection	✓	!
TGA/FDA/EMA Alignment Fully aligned	✓	!

43.5%
R&D Cash Rebate
 e.g., AU\$5M programme, returns >AU\$2M
 offsetting entire tech transfer expense



Aurora Biosynthetics
One GMP site. One quality system. One regulatory filing
 End-to-end RNA manufacturing
 includes PD, AD, fill/finish
 In-house QC testing
 Regulatory support




No other CDMO jurisdiction offers this combination, 43.5% cash rebate, Five Eyes IP, and BIOSECURE compliance

Fragmented Manufacturing Model

Brings Unnecessary Risks to Sponsors

Fragmented Model (1) compounds collaboration costs, (2) adds process risks and (3) increases risk of program delays from each site handoff



+ Process Development · Analytical Development · QC — each scattered across multiple labs

Aurora Biosynthetics Solve the Trilemma. All Three. One Site.

Our integrated single-site model eliminates the well-known trade-off



Speed

No site transfers and simplified supply chain
PD → pDNA → mRNA → LNP → Fill/Finish + QC under one roof

Quality

One QMS and phase appropriate development
TGA-regulated facility aligned with FDA and EMA standards

Cost

+

43.5% R&D Tax Incentive (cash rebate)*
Efficient to secure from Australian Government

*Eligibility subject to ATO R&D Tax Incentive guidelines.

Your Program, Your Scope

Engage Aurora for individual services or the full chain - One site, one quality system, one point of accountability



Process & Analytical Dev

- ✓ Experienced RNA team with FIH mRNA-LNP track record
- ✓ In-house PD/AD co-located with GMP = no site transfers
- ✓ Stage-specific optimization from sequence to your TPP



pDNA Production

- ✓ Cell banking through linearized template under one QMS
- ✓ Co-located with downstream mRNA manufacturing = no hand-offs
- ✓ Single supply chain reduces risk and timelines



GMP mRNA Manufacturing

- ✓ Seamless scale-up from PD to GMP under one roof
- ✓ Build or transfer analytical methods alongside your process
- ✓ Batch release for clinical supply



GMP LNP Formulation

- ✓ Certified LNP formulation and encapsulation capability
- ✓ Support evaluation of preferred LNP platforms and libraries
- ✓ Formulation of RNA and other API



Aseptic Fill / Finish

- ✓ Automated robotic aseptic fill technology
- ✓ Vial formats at clinical and commercial scale
- ✓ Dedicated aseptic suites with environmental monitoring

Your Path to Translation Enabled by an Experienced Partner

REACH OUT TO OUR TEAM

Elben Guimaraes

Head of GMP Manufacturing

eguimaraes@aurorabiosynthetics.com

Bryan Aman

Senior Manager, Business Development
& Commercial Operations

baman@aurorabiosynthetics.com